0000874015-19-000154.txt : 20191220 0000874015-19-000154.hdr.sgml : 20191220 20191220192312 ACCESSION NUMBER: 0000874015-19-000154 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191220 FILED AS OF DATE: 20191220 DATE AS OF CHANGE: 20191220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HOUGEN ELIZABETH L CENTRAL INDEX KEY: 0001074773 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 191303177 MAIL ADDRESS: STREET 1: 10070 BARNES CANYON ROAD STREET 2: C/O MOLECULAR BIOSYSTEMS INC CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-12-20 0000874015 IONIS PHARMACEUTICALS INC IONS 0001074773 HOUGEN ELIZABETH L C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP, Finance & CFO Common Stock 2019-12-20 2019-12-20 4 M 0 7196 10.82 A 27251 D Common Stock 2019-12-20 2019-12-20 4 F 0 4215 61.52 D 23036 D Common Stock 2019-12-20 2019-12-20 4 M 0 3438 10.82 A 26474 D Common Stock 2019-12-20 2019-12-20 4 F 0 2014 61.52 D 24460 D Employee Stock Option (right to buy) 10.82 2019-12-20 2019-12-20 4 M 0 7196 0 D 2017-01-02 2020-01-01 Common Stock 7196 0 D Employee Stock Option (right to buy) 10.82 2019-12-20 2019-12-20 4 M 0 3438 0 D 2017-01-02 2020-01-01 Common Stock 3438 0 D Acquired as a result of exercising a stock option in accordance with the Amendment to Outstanding Options Agreement dated November 9, 2015 between the reporting person and issuer ("Agreement"). The purchase and partial sale reported on this Form 4 was effective pursuant to the Agreement. Shares sold to cover the option cost and tax withholding obligations pursuant to the Agreement. Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. /s/Patrick R. O'Neil, attorney-in-fact 2019-12-20